Brown LG - Search Results

1

Inhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bone.

Kirk PS, Koreckij T, Nguyen HM, Brown LG, Snyder LA, Vessella RL, Corey E. Kirk PS, et al. Among authors: brown lg. Int J Mol Sci. 2013 May 21;14(5):10483-96. doi: 10.3390/ijms140510483. Int J Mol Sci. 2013. PMID: 23698775 Free PMC article.

2

A very sensitive coupled luminescent assay for cytotoxicity and complement-mediated lysis.

Corey MJ, Kinders RJ, Brown LG, Vessella RL. Corey MJ, et al. Among authors: brown lg. J Immunol Methods. 1997 Aug 22;207(1):43-51. doi: 10.1016/s0022-1759(97)00098-7. J Immunol Methods. 1997. PMID: 9328585

3

LNCaP produces both putative zymogen and inactive, free form of prostate-specific antigen.

Corey E, Brown LG, Corey MJ, Buhler KR, Vessella RL. Corey E, et al. Among authors: brown lg. Prostate. 1998 May;35(2):135-43. doi: 10.1002/(sici)1097-0045(19980501)35:2<135::aid-pros7>3.0.co;2-i. Prostate. 1998. PMID: 9568677

4

Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo.

Melchior SW, Brown LG, Figg WD, Quinn JE, Santucci RA, Brunner J, Thüroff JW, Lange PH, Vessella RL. Melchior SW, et al. Among authors: brown lg. Int J Oncol. 1999 Mar;14(3):501-8. doi: 10.3892/ijo.14.3.501. Int J Oncol. 1999. PMID: 10024683

5

Mechanistic studies of the effects of anti-factor H antibodies on complement-mediated lysis.

Corey MJ, Kinders RJ, Poduje CM, Bruce CL, Rowley H, Brown LG, Hass GM, Vessella RL. Corey MJ, et al. Among authors: brown lg. J Biol Chem. 2000 Apr 28;275(17):12917-25. doi: 10.1074/jbc.275.17.12917. J Biol Chem. 2000. PMID: 10777591 Free article.

6

Identification of the target of monoclonal antibody A6H as dipeptidyl peptidase IV/CD26 by LC MS\MS.

Hass GM, Meyer JL, Newitt RA, Labuda T, Brown L, Aebersold R, Vessella RL. Hass GM, et al. Hybridoma. 2001 Aug;20(4):231-6. doi: 10.1089/027245701753179802. Hybridoma. 2001. PMID: 11604108

7

Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol.

Corey E, Quinn JE, Emond MJ, Buhler KR, Brown LG, Vessella RL. Corey E, et al. Among authors: brown lg. Clin Cancer Res. 2002 Apr;8(4):1003-7. Clin Cancer Res. 2002. PMID: 11948106

8

Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells.

Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL. Corey E, et al. Among authors: brown lg, brown jm. Prostate. 2002 Jun 1;52(1):20-33. doi: 10.1002/pros.10091. Prostate. 2002. PMID: 11992617

9

A novel monoclonal antibody 107-1A4 with high prostate specificity: generation, characterization of antigen expression, and targeting of human prostate cancer xenografts.

Brown LG, Wegner SK, Wang H, Buhler KR, Arfman EW, Lange PH, Vessella RL. Brown LG, et al. Prostate Cancer Prostatic Dis. 1998 Jun;1(4):208-215. doi: 10.1038/sj.pcan.4500233. Prostate Cancer Prostatic Dis. 1998. PMID: 12496897

10

Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.

Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL. Corey E, et al. Among authors: brown lg. Clin Cancer Res. 2003 Jan;9(1):295-306. Clin Cancer Res. 2003. PMID: 12538482

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

210 results

Search Page

Filters